TEVA-FEBUXOSTAT TABLET Canada - engelsk - Health Canada

teva-febuxostat tablet

teva canada limited - febuxostat (febuxostat hemihydrate) - tablet - 80mg - febuxostat (febuxostat hemihydrate) 80mg - antigout agents

Febuxostat Rowex 80 mg Film-coated Tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

febuxostat rowex 80 mg film-coated tablets

rowex ltd - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat

Febuxostat Rowex 120 mg Film-coated Tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

febuxostat rowex 120 mg film-coated tablets

rowex ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Febuxostat Clonmel 80 mg Film-coated tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

febuxostat clonmel 80 mg film-coated tablets

clonmel healthcare ltd - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat

Febuxostat Clonmel 120 mg Film-coated tablets Irland - engelsk - HPRA (Health Products Regulatory Authority)

febuxostat clonmel 120 mg film-coated tablets

clonmel healthcare ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

FEBUXOSTAT tablet, coated USA - engelsk - NLM (National Library of Medicine)

febuxostat tablet, coated

alembic pharmaceuticals limited - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. for the safe and effective use of allopurinol, see allopurinol prescribing information. limitations of use : febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia. febuxostat tablets are contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions ( 7)] . risk summary   limited available data with febuxostat tablets use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal expos

Febuxostat AB 120 mg film-coat. tabl. Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

febuxostat ab 120 mg film-coat. tabl.

aurobindo sa-nv - febuxostat 120 mg - film-coated tablet - 120 mg - febuxostat 120 mg - febuxostat

Febuxostat AB 80 mg film-coat. tabl. Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

febuxostat ab 80 mg film-coat. tabl.

aurobindo sa-nv - febuxostat 80 mg - film-coated tablet - 80 mg - febuxostat 80 mg - febuxostat

Febuxostat EG 80 mg film-coat. tabl. Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

febuxostat eg 80 mg film-coat. tabl.

eg sa-nv - febuxostat hemihydrate 82 mg - eq. febuxostat 80 mg - film-coated tablet - 80 mg - febuxostat hemihydrate 82 mg - febuxostat

Febuxostat EG 120 mg film-coat. tabl. Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

febuxostat eg 120 mg film-coat. tabl.

eg sa-nv - febuxostat hemihydrate 123,4 mg - eq. febuxostat 120 mg - film-coated tablet - 120 mg - febuxostat hemihydrate 123.4 mg - febuxostat